Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $322.2 million.

  • Syndax Pharmaceuticals' Total Non-Current Liabilities rose 1610865000.0% to $322.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $322.2 million, marking a year-over-year increase of 1610865000.0%. This contributed to the annual value of $333.1 million for FY2024, which is 5655697.28% up from last year.
  • As of Q3 2025, Syndax Pharmaceuticals' Total Non-Current Liabilities stood at $322.2 million, which was up 1610865000.0% from $325.7 million recorded in Q2 2025.
  • In the past 5 years, Syndax Pharmaceuticals' Total Non-Current Liabilities ranged from a high of $333.1 million in Q4 2024 and a low of $2000.0 during Q3 2024
  • For the 5-year period, Syndax Pharmaceuticals' Total Non-Current Liabilities averaged around $75.3 million, with its median value being $11.8 million (2021).
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Total Non-Current Liabilities tumbled by 9976.85% in 2024, and later skyrocketed by 1610865000.0% in 2025.
  • Quarter analysis of 5 years shows Syndax Pharmaceuticals' Total Non-Current Liabilities stood at $20.6 million in 2021, then crashed by 96.5% to $722000.0 in 2022, then dropped by 18.56% to $588000.0 in 2023, then surged by 56556.97% to $333.1 million in 2024, then dropped by 3.29% to $322.2 million in 2025.
  • Its Total Non-Current Liabilities stands at $322.2 million for Q3 2025, versus $325.7 million for Q2 2025 and $331.1 million for Q1 2025.